Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
企業コードASRT
会社名Assertio Holdings Inc
上場日Feb 12, 1997
最高経営責任者「CEO」Mr. Brendan P. O'Grady
従業員数58
証券種類Ordinary Share
決算期末Feb 12
本社所在地100 S. Saunders Road
都市LAKE FOREST
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号60045
電話番号12244197106
ウェブサイトhttps://www.assertiotx.com/
企業コードASRT
上場日Feb 12, 1997
最高経営責任者「CEO」Mr. Brendan P. O'Grady
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし